EN IT

Oncologia Personalizzata

XEPTAGEN SpA è attivamente impegnata nella scoperta e nella validazione di nuovi marcatori per migliorare la gestione clinica del paziente oncologico sviluppando trattamenti terapeutici personalizzati.

Products Highlight

Latest Product Literature

Clinical evaluation of the iXip index to reduce prostate re-biopsies. Cancer Treat Res Comm. 16:59-63. 2018.

Development of a novel diagnostic algorithm to predict NASH in HCV-positive patients. Int J Biol Markers. eISSN 1724-6008. 2018.

The protease-inhibitor SerpinB3 outlines a stem-like subset in human cholangiocarcinoma. Dig Liver Dis. 50(S1):47. 2018.

Low levels of squamous cell carcinoma antigen–IgM complexes in serum are predictors of better survival in patients with liver cirrhosis. Dig Liver Dis. 50(S1):42. 2018.

Serum and bile squamous cell carcinoma antigen detection: a new prognostic marker in patients with perihilar cholangiocarcinoma. Dig Liver Dis. 50(S1):40. 2018.

Role of SERPINB3 like serological and molecular biomarker into NASH development and progression. Dig Liver Dis. 50(S1):18. 2018.


Comunicati stampa

Youtube

Tweets by Xeptagen